Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2020 Feb 25;11:234. doi: 10.3389/fimmu.2020.00234

Corrigendum: Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS–) vs. Alternatively Activated Macrophages

Marco Orecchioni 1, Yanal Ghosheh 1, Akula Bala Pramod 1, Klaus Ley 1,2,*,
PMCID: PMC7053374  PMID: 32161587

In the original article, there was a mistake in Figure 3 as published. Three gene names were misspelled in the previous version. In Figure 3A, M1(=LPS+) panel, the correct gene name for EIFE3 is EIF4E3. In Figure 3B, alternatively activated (IL-4) panel, the correct gene name for WRD4 is WDR4. Also in Figure 3B, the correct gene name for POLRR3K is POLR3K. The corrected Figure 3 appears below.

Figure 3.

Figure 3

In vivo macrophage signatures predict survival in osteosarcoma cancer biopsy transcriptomes. Survival data for human osteosarcoma cancer biopsies (GSE21257) were analyzed for the impact of M1(=LPS+) and classically activated (LPS+IFN-γ) (A) and M2(=LPS−) and alternatively activated (IL-4) (B) gene expression signatures in the tumor biopsy transcriptome. Kaplan–Meier curves were plotted using ProggeneV2, divided by the median of the mean expression of a tumor-specific gene list (in boxes). Hazard ratio (HR, cox proportional hazard analysis) and significance (log rank P-value) are shown. Red, green curves indicate high, low expression of the respective signature genes. The two vertical black lines indicates 3 and 5 years, respectively.

Additionally, in the original article, there was a mistake in the legend for Figure 3 as published. “M1(=LPS+)” was written as “M1(LPS+)”, and “M2(=LPS−)” was written as “M2(LPS−)”. The correct legend for Figure 3 appears below.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES